[Skip to Content]
[Skip to Content Landing]
Citations 0
Letters
July 5, 2006

Medical Management of Peripheral Arterial Disease

Author Affiliations
 

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2006;296(1):41-42. doi:10.1001/jama.296.1.41-b

To the Editor: In discussing medical treatment of PAD, Dr Hankey and colleagues1 state that “a meta-analysis of 8 [randomized controlled trials] involving 2702 patients demonstrated that cilostazol improved maximum walking distance and pain-free walking distance,” citing Thompson et al.2 However, in that study, the effect size was small, with increases of 50% and 67% in maximum walking distance and pain-free walking distance, respectively. Stated differently, if a patient could walk to first base before experiencing claudication, then with the addition of cilostazol, with its potential toxicity and at a cost in our pharmacy of $467.78 per month, he or she could round first and make it part of the way to second base.

First Page Preview View Large
First page PDF preview
First page PDF preview
×